Is tezepelumab a treatment option for severe asthma patients with low inflammation?
Tezepelumab is a biologic drug that blocks TSLP, an alarmin cytokine involved in asthma inflammation. Unlike other biologics that target specific type 2 pathways (e.g., eosinophilic inflammation), tezepelumab works upstream and is approved for severe asthma without requiring high levels of type 2 biomarkers. This means it is a treatment option for patients with low inflammation, also called type 2-low asthma, although research shows the benefit may be somewhat smaller in this group.
What the research says
Tezepelumab is the first biologic approved for severe asthma without phenotype or biomarker restrictions, including type 2-low disease 2. In the phase 3 NAVIGATOR and DESTINATION studies, tezepelumab reduced exacerbations and improved clinical remission regardless of baseline blood eosinophil counts or FeNO levels 6. The CASCADE trial showed tezepelumab reduced airway inflammatory cells and hyperresponsiveness in patients with moderate-to-severe uncontrolled asthma, irrespective of type 2 biomarker levels 7. A PATHWAY analysis confirmed that tezepelumab reduced exacerbations by 55-83% versus placebo across all baseline biomarker levels, including those with low eosinophils or low FeNO 8. However, the magnitude of benefit is somewhat smaller in type 2-low patients 2. A systematic review of biologic switching found tezepelumab was used as a switch option, often after other biologics failed, and switching generally improved outcomes 1.
What to ask your doctor
- Would tezepelumab be appropriate for my type of asthma inflammation, even if my eosinophil or FeNO levels are low?
- What is the expected benefit of tezepelumab for someone with low type 2 inflammation compared to other biologics?
- How does tezepelumab differ from other biologics I might have tried or considered?
- What are the potential side effects or risks of tezepelumab for me?
- How is tezepelumab administered and how often would I need treatment?
This question is drawn from common patient questions about Pulmonology & Critical Care and answered using cited medical research. We do not provide individualized advice.